Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut–liver axis

References

• Abernathy, B. E., T. C. Schoenfuss, A. S. Bailey, and D. D. Gallaher. 2021. Polylactose exhibits prebiotic activity and reduces adiposity and nonalcoholic fatty liver disease in rats fed a high-fat diet. The Journal of Nutrition 151 (2):352–60. doi: 10.1093/jn/nxaa376.
   PubMed Web of Science ®Google Scholar
• Adhikari, A. A., T. C. M. Seegar, S. B. Ficarro, M. D. Mccurry, D. Ramachandran, L. Yao, S. N. Chaudhari, S. Ndousse-Fetter, A. S. Banks, J. A. Marto, et al. 2020. Development of a covalent inhibitor of gut bacterial bile salt hydrolases. Nature Chemical Biology 16 (3):318–26. doi: 10.1038/s41589-020-0467-3.
   PubMed Web of Science ®Google Scholar
• Albillos, A., A. de Gottardi, and M. Rescigno. 2020. The gut-liver axis in liver disease: Pathophysiological basis for therapy. Journal of Hepatology 72 (3):558–77. doi: 10.1016/j.jhep.2019.10.003.
   PubMed Web of Science ®Google Scholar
• Alisi, A., G. Bedogni, G. Baviera, V. Giorgio, E. Porro, C. Paris, P. Giammaria, L. Reali, F. Anania, and V. Nobili. 2014. Randomised clinical trial: The beneficial effects of vsl#3 in obese children with non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 39 (11):1276–85. doi: 10.1111/apt.12758.
   PubMed Web of Science ®Google Scholar
• Aragonès, G., M. Colom-Pellicer, C. Aguilar, E. Guiu-Jurado, S. Martínez, F. Sabench, J. A. Porras, D. Riesco, D. Del Castillo, C. Richart, et al. 2020. Circulating microbiota-derived metabolites: A "liquid biopsy?International Journal of Obesity (2005) 44 (4):875–85. doi: 10.1038/s41366-019-0430-0.
   PubMed Web of Science ®Google Scholar
• Armstrong, M. J., P. Gaunt, G. P. Aithal, D. Barton, D. Hull, R. Parker, J. M. Hazlehurst, K. Guo, G. Abouda, M. A. Aldersley, et al. 2016. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (lean): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet 387 (10019):679–90. doi: 10.1016/S0140-6736(15)00803-X.
   PubMed Web of Science ®Google Scholar
• Aron-Wisnewsky, J., C. Vigliotti, J. Witjes, P. Le, A. G. Holleboom, J. Verheij, M. Nieuwdorp, and K. Clément. 2020a. Gut microbiota and human nafld: Disentangling microbial signatures from metabolic disorders. Nature Reviews. Gastroenterology & Hepatology 17 (5):279–97. doi: 10.1038/s41575-020-0269-9.
   PubMed Web of Science ®Google Scholar
• Aron-Wisnewsky, J., M. V. Warmbrunn, M. Nieuwdorp, and K. Clément. 2020b. Nonalcoholic fatty liver disease: Modulating gut microbiota to improve severity?Gastroenterology 158 (7):1881–98. doi: 10.1053/j.gastro.2020.01.049.
   PubMed Web of Science ®Google Scholar
• Auguet, T., L. Bertran, J. Binetti, C. Aguilar, S. Martínez, F. Sabench, J. M. Lopez-Dupla, J. A. Porras, D. Riesco, D. D. Castillo, et al. 2020. Relationship between il-8 circulating levels and tlr2 hepatic expression in women with morbid obesity and nonalcoholic steatohepatitis. International Journal of Molecular Sciences 21 (11):4189. doi: 10.3390/ijms21114189.
   PubMed Web of Science ®Google Scholar
• Barrow, F., S. Khan, G. Fredrickson, H. Wang, K. Dietsche, P. Parthiban, S. Robert, T. Kaiser, S. Winer, A. Herman, et al. 2021. Microbiota-driven activation of intrahepatic b cells aggravates nonalcoholic steatohepatitis through innate and adaptive signaling. Hepatology (Baltimore, Md). doi: 10.1002/hep.31755.
   Google Scholar
• Beaumont, M., A. M. Neyrinck, M. Olivares, J. Rodriguez, A. De Rocca Serra, M. Roumain, L. B. Bindels, P. D. Cani, P. Evenepoel, G. G. Muccioli, et al. 2018. The gut microbiota metabolite indole alleviates liver inflammation in mice. FASEB Journal 32 (12):fj201800544. doi: 10.1096/fj.201800544.
   PubMed Web of Science ®Google Scholar
• Behary, J., N. Amorim, X. T. Jiang, A. Raposo, L. Gong, E. Mcgovern, R. Ibrahim, F. Chu, C. Stephens, H. Jebeili, et al. 2021. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun 12 (1):187. doi: 10.1038/s41467-020-20422-7.
   PubMed Web of Science ®Google Scholar
• Beisner, J., L. Filipe Rosa, V. Kaden-Volynets, I. Stolzer, C. Günther, and S. C. Bischoff. 2021. Prebiotic inulin and sodium butyrate attenuate obesity-induced intestinal barrier dysfunction by induction of antimicrobial peptides. Frontiers in Immunology 12:678360. doi: 10.3389/fimmu.2021.678360.
   PubMed Web of Science ®Google Scholar
• Bifari, F., R. Manfrini, M. Dei Cas, C. Berra, M. Siano, M. Zuin, R. Paroni, and F. Folli. 2018. Multiple target tissue effects of glp-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacological Research 137:219–29. doi: 10.1016/j.phrs.2018.09.025.
   PubMed Web of Science ®Google Scholar
• Bomhof, M. R., J. A. Parnell, H. R. Ramay, P. Crotty, K. P. Rioux, C. S. Probert, S. Jayakumar, M. Raman, and R. A. Reimer. 2019. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial. European Journal of Nutrition 58 (4):1735–45. doi: 10.1007/s00394-018-1721-2.
   PubMed Web of Science ®Google Scholar
• Boursier, J., O. Mueller, M. Barret, M. Machado, L. Fizanne, F. Araujo-Perez, C. D. Guy, P. C. Seed, J. F. Rawls, L. A. David, et al. 2016. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology (Baltimore, Md.) 63 (3):764–75. doi: 10.1002/hep.28356.
   PubMed Web of Science ®Google Scholar
• Brandl, K., P. Hartmann, L. J. Jih, D. P. Pizzo, J. Argemi, M. Ventura-Cots, S. Coulter, C. Liddle, L. Ling, S. J. Rossi, et al. 2018. Dysregulation of serum bile acids and fgf19 in alcoholic hepatitis. Journal of Hepatology 69 (2):396–405. doi: 10.1016/j.jhep.2018.03.031.
   PubMed Web of Science ®Google Scholar
• Brandl, K., V. Kumar, and L. Eckmann. 2017. Gut-liver axis at the frontier of host-microbial interactions. American Journal of Physiology. Gastrointestinal and Liver Physiology 312 (5):G413–G419. doi: 10.1152/ajpgi.00361.2016.
   PubMed Web of Science ®Google Scholar
• Bril, F., D. Barb, P. Portillo-Sanchez, D. Biernacki, R. Lomonaco, A. Suman, M. H. Weber, J. T. Budd, M. E. Lupi, and K. Cusi. 2017. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology 65 (4):1132–44. doi: 10.1002/hep.28985.
   PubMed Web of Science ®Google Scholar
• Brown, A. J., S. M. Goldsworthy, A. A. Barnes, M. M. Eilert, L. Tcheang, D. Daniels, A. I. Muir, M. J. Wigglesworth, I. Kinghorn, N. J. Fraser, et al. 2003. The orphan g protein-coupled receptors gpr41 and gpr43 are activated by propionate and other short chain carboxylic acids. The Journal of Biological Chemistry 278 (13):11312–9. doi: 10.1074/jbc.M211609200.
   PubMed Web of Science ®Google Scholar
• Cai, J., X. J. Zhang, and H. Li. 2018. Role of innate immune signaling in non-alcoholic fatty liver disease. Trends in Endocrinology and Metabolism: TEM 29 (10):712–22. doi: 10.1016/j.tem.2018.08.003.
   PubMed Web of Science ®Google Scholar
• Canfora, E. E., R. C. R. Meex, K. Venema, and E. E. Blaak. 2019. Gut microbial metabolites in obesity, nafld and t2dm. Nature Reviews. Endocrinology 15 (5):261–73. doi: 10.1038/s41574-019-0156-z.
   PubMed Web of Science ®Google Scholar
• Carpino, G., M. Del Ben, D. Pastori, R. Carnevale, F. Baratta, D. Overi, H. Francis, V. Cardinale, P. Onori, S. Safarikia, et al. 2020. Increased liver localization of lipopolysaccharides in human and experimental nafld. Hepatology (Baltimore, Md.) 72 (2):470–85. doi: 10.1002/hep.31056.
   PubMed Web of Science ®Google Scholar
• Carreres, L., Z. M. Jílková, G. Vial, P. N. Marche, T. Decaens, and H. Lerat. 2021. Modeling diet-induced NAFLD and NASH in rats: A comprehensive review. Biomedicines 9 (4):378. doi: 10.3390/biomedicines9040378.
   PubMed Web of Science ®Google Scholar
• Chang, C. S., and C. Y. Kao. 2019. Current understanding of the gut microbiota shaping mechanisms. Journal of Biomedical Science 26 (1):59. doi: 10.1186/s12929-019-0554-5.
   PubMed Web of Science ®Google Scholar
• Chen, F., S. Esmaili, G. B. Rogers, E. Bugianesi, S. Petta, G. Marchesini, A. Bayoumi, M. Metwally, M. K. Azardaryany, S. Coulter, et al. 2020a. Lean nafld: A distinct entity shaped by differential metabolic adaptation. Hepatology 71 (4):1213–27. doi: 10.1002/hep.30908.
   PubMed Web of Science ®Google Scholar
• Chen, M., W. L. Guo, Q. Y. Li, J. X. Xu, Y. J. Cao, B. Liu, X. D. Yu, P. F. Rao, L. Ni, and X. C. Lv. 2020b. The protective mechanism of lactobacillus plantarum fzu3013 against non-alcoholic fatty liver associated with hyperlipidemia in mice fed a high-fat diet. Food & Function 11 (4):3316–31. doi: 10.1039/c9fo03003d.
   PubMed Web of Science ®Google Scholar
• Chen, Y. M., Y. Liu, R. F. Zhou, X. L. Chen, C. Wang, X. Y. Tan, L. J. Wang, R. D. Zheng, H. W. Zhang, W. H. Ling, et al. 2016. Associations of gut-flora-dependent metabolite trimethylamine-n-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Scientific Reports 6 (1):19076. doi: 10.1038/srep19076.
   PubMedGoogle Scholar
• Chenxu, G., X. Minxuan, Q. Yuting, G. Tingting, F. Jing, L. Jinxiao, W. Sujun, M. Yongjie, L. Deshuai, L. Qiang, et al. 2019. Loss of rip3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis: A mechanism involving toll-like receptor 4 and oxidative stress. Free Radical Biology & Medicine 134:23–41. doi: 10.1016/j.freeradbiomed.2018.12.034.
   PubMed Web of Science ®Google Scholar
• Choi, W., J. Namkung, I. Hwang, H. Kim, A. Lim, H. J. Park, H. W. Lee, K. H. Han, S. Park, J. S. Jeong, et al. 2018. Serotonin signals through a gut-liver axis to regulate hepatic steatosis. Nature Communications 9 (1):4824. doi: 10.1038/s41467-018-07287-7.
   PubMedGoogle Scholar
• Chong, P. L., D. Laight, R. J. Aspinall, A. Higginson, and M. H. Cummings. 2021. A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. BMC Gastroenterology 21 (1):144. doi: 10.1186/s12876-021-01660-5.
   PubMed Web of Science ®Google Scholar
• Chu, H., Y. Duan, L. Yang, and B. Schnabl. 2019. Small metabolites, possible big changes: A microbiota-centered view of non-alcoholic fatty liver disease. Gut 68 (2):359–70. doi: 10.1136/gutjnl-2018-316307.
   PubMed Web of Science ®Google Scholar
• Chu, H., and S. K. Mazmanian. 2013. Innate immune recognition of the microbiota promotes host-microbial symbiosis. Nature Immunology 14 (7):668–75. doi: 10.1038/ni.2635.
   PubMed Web of Science ®Google Scholar
• Cope, K., T. Risby, and A. M. Diehl. 2000. Increased gastrointestinal ethanol production in obese mice: Implications for fatty liver disease pathogenesis. Gastroenterology 119 (5):1340–7. doi: 10.1053/gast.2000.19267.
   PubMed Web of Science ®Google Scholar
• Corbin, K. D., and S. H. Zeisel. 2012. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Current Opinion in Gastroenterology 28 (2):159–65. doi: 10.1097/MOG.0b013e32834e7b4b.
   PubMed Web of Science ®Google Scholar
• Corbitt, N., S. Kimura, K. Isse, S. Specht, L. Chedwick, B. R. Rosborough, J. G. Lunz, N. Murase, S. Yokota, and A. J. Demetris. 2013. Gut bacteria drive kupffer cell expansion via mamp-mediated icam-1 induction on sinusoidal endothelium and influence preservation-reperfusion injury after orthotopic liver transplantation. The American Journal of Pathology 182 (1):180–91. doi: 10.1016/j.ajpath.2012.09.010.
   PubMed Web of Science ®Google Scholar
• Cortez-Pinto, H., P. Borralho, J. Machado, M. T. Lopes, I. V. Gato, A. M. Santos, and A. S. Guerreiro. 2016. Microbiota modulation with synbiotic decreases liver fibrosis in a high fat choline deficient diet mice model of non-alcoholic steatohepatitis (NASH). GE Portuguese Journal of Gastroenterology 23 (3):132–41. doi: 10.1016/j.jpge.2016.01.004.
   PubMedGoogle Scholar
• Craven, L., A. Rahman, S. Nair Parvathy, M. Beaton, J. Silverman, K. Qumosani, I. Hramiak, R. Hegele, T. Joy, J. Meddings, et al. 2020. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial. The American Journal of Gastroenterology 115 (7):1055–65. doi: 10.14309/ajg.0000000000000661.
   PubMed Web of Science ®Google Scholar
• Degirolamo, C., S. Rainaldi, F. Bovenga, S. Murzilli, and A. Moschetta. 2014. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the fxr-fgf15 axis in mice. Cell Reports 7 (1):12–8. doi: 10.1016/j.celrep.2014.02.032.
   PubMed Web of Science ®Google Scholar
• Del Chierico, F., V. Nobili, P. Vernocchi, A. Russo, C. De Stefanis, D. Gnani, C. Furlanello, A. Zandonà, P. Paci, G. Capuani, et al. 2017. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology (Baltimore, Md.) 65 (2):451–64. doi: 10.1002/hep.28572.
   PubMed Web of Science ®Google Scholar
• Dey, P., B. D. Olmstead, G. Y. Sasaki, Y. Vodovotz, Z. Yu, and R. S. Bruno. 2020. Epigallocatechin gallate but not catechin prevents nonalcoholic steatohepatitis in mice similar to green tea extract while differentially affecting the gut microbiota. The Journal of Nutritional Biochemistry 84:108455. doi: 10.1016/j.jnutbio.2020.108455.
   PubMed Web of Science ®Google Scholar
• Dumas, M. E., R. H. Barton, A. Toye, O. Cloarec, C. Blancher, A. Rothwell, J. Fearnside, R. Tatoud, V. Blanc, J. C. Lindon, et al. 2006. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proceedings of the National Academy of Sciences of the United States of America 103 (33):12511–6. doi: 10.1073/pnas.0601056103.
   PubMed Web of Science ®Google Scholar
• Engelmann, C., M. Sheikh, S. Sharma, T. Kondo, H. Loeffler-Wirth, Y. B. Zheng, S. Novelli, A. Hall, A. J. C. Kerbert, J. Macnaughtan, et al. 2020. Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure. Journal of Hepatology 73 (1):102–12. doi: 10.1016/j.jhep.2020.01.011.
   PubMed Web of Science ®Google Scholar
• Engstler, A. J., T. Aumiller, C. Degen, M. Dürr, E. Weiss, I. B. Maier, J. M. Schattenberg, C. J. Jin, C. Sellmann, and I. Bergheim. 2016. Insulin resistance alters hepatic ethanol metabolism: Studies in mice and children with non-alcoholic fatty liver disease. Gut 65 (9):1564–71. doi: 10.1136/gutjnl-2014-308379.
   PubMed Web of Science ®Google Scholar
• Francés, R., P. Zapater, J. M. González-Navajas, C. Muñoz, R. Caño, R. Moreu, S. Pascual, P. Bellot, M. Pérez-Mateo, and J. Such. 2008. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology (Baltimore, Md.) 47 (3):978–85. doi: 10.1002/hep.22083.
   PubMed Web of Science ®Google Scholar
• Friedman, E. S., Y. Li, T. D. Shen, J. Jiang, L. Chau, L. Adorini, F. Babakhani, J. Edwards, D. Shapiro, C. Zhao, et al. 2018. Fxr-dependent modulation of the human small intestinal microbiome by the bile acid derivative obeticholic acid. Gastroenterology 155 (6):1741–52.e5. doi: 10.1053/j.gastro.2018.08.022.
   PubMed Web of Science ®Google Scholar
• Funabashi, M., T. L. Grove, M. Wang, Y. Varma, M. E. Mcfadden, L. C. Brown, C. Guo, S. Higginbottom, S. C. Almo, and M. A. Fischbach. 2020. A metabolic pathway for bile acid dehydroxylation by the gut microbiome. Nature 582 (7813):566–70. doi: 10.1038/s41586-020-2396-4.
   PubMed Web of Science ®Google Scholar
• García-Alonso, F. J., R. González-Barrio, G. Martín-Pozuelo, N. Hidalgo, I. Navarro-González, D. Masuero, E. Soini, U. Vrhovsek, and M. J. Periago. 2017. A study of the prebiotic-like effects of tomato juice consumption in rats with diet-induced non-alcoholic fatty liver disease (nafld). Food & Function 8 (10):3542–52. doi: 10.1039/c7fo00393e.
   PubMed Web of Science ®Google Scholar
• Geier, A., D. Tiniakos, H. Denk, and M. Trauner. 2021. From the origin of nash to the future of metabolic fatty liver disease. Gut. 70 (8):1570–1579. doi: 10.1136/gutjnl-2020-323202.
   PubMed Web of Science ®Google Scholar
• Ghosh, S., X. Yang, L. Wang, C. Zhang, and L. Zhao. 2021. Active phase prebiotic feeding alters gut microbiota, induces weight-independent alleviation of hepatic steatosis and serum cholesterol in high-fat diet-fed mice. Computational and Structural Biotechnology Journal 19:448–58. doi: 10.1016/j.csbj.2020.12.011.
   PubMed Web of Science ®Google Scholar
• Giorgio, V., L. Miele, L. Principessa, F. Ferretti, M. P. Villa, V. Negro, A. Grieco, A. Alisi, and V. Nobili. 2014. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Digestive and Liver Disease 46 (6):556–60. doi: 10.1016/j.dld.2014.02.010.
   Web of Science ®Google Scholar
• Gonzalez, F. J., C. Jiang, and A. D. Patterson. 2016. An intestinal microbiota-farnesoid x receptor axis modulates metabolic disease. Gastroenterology 151 (5):845–59. doi: 10.1053/j.gastro.2016.08.057.
   PubMed Web of Science ®Google Scholar
• Grzych, G., L. Vonghia, M. A. Bout, J. Weyler, A. Verrijken, E. Dirinck, M. J. Chevalier Curt, L. Van Gaal, R. Paumelle, S. Francque, et al. 2020. Plasma bcaa changes in patients with nafld are sex dependent. The Journal of Clinical Endocrinology and Metabolism 105 (7):dgaa175. doi: 10.1210/clinem/dgaa175.
   PubMed Web of Science ®Google Scholar
• Guarner, C., J. M. González-Navajas, E. Sánchez, G. Soriando, R. Francés, M. Chiva, P. Zapater, S. Benlloch, C. Muñoz, S. Pascual, et al. 2006. The detection of bacterial DNA in blood of rats with ccl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology (Baltimore, Md.) 44 (3):633–9. doi: 10.1002/hep.21286.
   PubMed Web of Science ®Google Scholar
• Gupta, A., and S. Khanna. 2017. Fecal microbiota transplantation. JAMA 318 (1):102. doi: 10.1001/jama.2017.6466.
   PubMedGoogle Scholar
• Hintikka, J., S. Lensu, E. Mäkinen, S. Karvinen, M. Honkanen, J. Lindén, T. Garrels, S. Pekkala, and L. Lahti. 2021. Xylo-oligosaccharides in prevention of hepatic steatosis and adipose tissue inflammation: Associating taxonomic and metabolomic patterns in fecal microbiomes with biclustering. International Journal of Environmental Research and Public Health 18 (8):4049. doi: 10.3390/ijerph18084049.
   PubMed Web of Science ®Google Scholar
• Honda, T., M. Ishigami, F. Luo, M. Lingyun, Y. Ishizu, T. Kuzuya, K. Hayashi, I. Nakano, T. Ishikawa, G. G. Feng, et al. 2017. Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice. Metabolism 69:177–87. doi: 10.1016/j.metabol.2016.12.013.
   PubMed Web of Science ®Google Scholar
• Hong, Y., L. Sheng, J. Zhong, X. Tao, W. Zhu, J. Ma, J. Yan, A. Zhao, X. Zheng, G. Wu, et al. 2021. Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice. Gut Microbes 13 (1):1–20. doi: 10.1080/19490976.2021.1930874.
   PubMed Web of Science ®Google Scholar
• Hoyles, L., J. M. Fernández-Real, M. Federici, M. Serino, J. Abbott, J. Charpentier, C. Heymes, J. L. Luque, E. Anthony, R. H. Barton, et al. 2018. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nature Medicine 24 (7):1070–80. doi: 10.1038/s41591-018-0061-3.
   PubMed Web of Science ®Google Scholar
• Huang, J., W. Li, W. Liao, Q. Hao, D. Tang, D. Wang, Y. Wang, and G. Ge. 2020. Green tea polyphenol epigallocatechin-3-gallate alleviates nonalcoholic fatty liver disease and ameliorates intestinal immunity in mice fed a high-fat diet. Food & Function 11 (11):9924–35. doi: 10.1039/d0fo02152k.
   PubMed Web of Science ®Google Scholar
• Huang, F., X. Zheng, X. Ma, R. Jiang, W. Zhou, S. Zhou, Y. Zhang, S. Lei, S. Wang, J. Kuang, et al. 2019. Theabrownin from pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism. Nature Communications 10 (1):4971. doi: 10.1038/s41467-019-12896-x.
   PubMedGoogle Scholar
• Inagaki, T., A. Moschetta, Y. K. Lee, L. Peng, G. Zhao, M. Downes, R. T. Yu, J. M. Shelton, J. A. Richardson, J. J. Repa, et al. 2006. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proceedings of the National Academy of Sciences of the United States of America 103 (10):3920–5. doi: 10.1073/pnas.0509592103.
   PubMed Web of Science ®Google Scholar
• Iwao, M., K. Gotoh, M. Arakawa, M. Endo, K. Honda, M. Seike, K. Murakami, and H. Shibata. 2020. Supplementation of branched-chain amino acids decreases fat accumulation in the liver through intestinal microbiota-mediated production of acetic acid. Scientific Reports 10 (1):18768. doi: 10.1038/s41598-020-75542-3.
   PubMed Web of Science ®Google Scholar
• Jang, H. R., H. J. Park, D. Kang, H. Chung, M. H. Nam, Y. Lee, J. H. Park, and H. Y. Lee. 2019. A protective mechanism of probiotic lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption. Experimental & Molecular Medicine 51 (8):1–14. doi: 10.1038/s12276-019-0293-4.
   Google Scholar
• Ji, Y., Y. Gao, H. Chen, Y. Yin, and W. Zhang. 2019. Indole-3-acetic acid alleviates nonalcoholic fatty liver disease in mice via attenuation of hepatic lipogenesis, and oxidative and inflammatory stress. Nutrients 11 (9):2062. doi: 10.3390/nu11092062.
   PubMed Web of Science ®Google Scholar
• Jia, X., S. Lu, Z. Zeng, Q. Liu, Z. Dong, Y. Chen, Z. Zhu, Z. Hong, T. Zhang, G. Du, et al. 2020. Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma. Hepatology (Baltimore, Md.) 71 (3):893–906. doi: 10.1002/hep.30852.
   PubMed Web of Science ®Google Scholar
• Jiang, C., C. Xie, F. Li, L. Zhang, R. G. Nichols, K. W. Krausz, J. Cai, Y. Qi, Z. Z. Fang, S. Takahashi, et al. 2015. Intestinal farnesoid x receptor signaling promotes nonalcoholic fatty liver disease. Journal of Clinical Investigation 125 (1):386–402. doi: 10.1172/jci76738.
   PubMed Web of Science ®Google Scholar
• Jiao, A. R., H. Diao, B. Yu, J. He, J. Yu, P. Zheng, Z. Q. Huang, Y. H. Luo, J. Q. Luo, X. B. Mao, et al. 2018. Oral administration of short chain fatty acids could attenuate fat deposition of pigs. PloS One 13 (5):e0196867. doi: 10.1371/journal.pone.0196867.
   PubMed Web of Science ®Google Scholar
• Jia, L., C. R. Vianna, M. Fukuda, E. D. Berglund, C. Liu, C. Tao, K. Sun, T. Liu, M. J. Harper, C. E. Lee, et al. 2014. Hepatocyte toll-like receptor 4 regulates obesity-induced inflammation and insulin resistance. Nature Communications 5:3878. doi: 10.1038/ncomms4878.
   PubMed Web of Science ®Google Scholar
• Jin, C. J., C. Sellmann, A. J. Engstler, D. Ziegenhardt, and I. Bergheim. 2015. Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH). The British Journal of Nutrition 114 (11):1745–55. doi: 10.1017/s0007114515003621.
   PubMed Web of Science ®Google Scholar
• Junker, A. E., L. L. Gluud, G. Van Hall, J. J. Holst, F. K. Knop, and T. Vilsbøll. 2016. Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. Journal of Hepatology 64 (4):908–15. doi: 10.1016/j.jhep.2015.11.014.
   PubMed Web of Science ®Google Scholar
• Koeth, R. A., Z. Wang, B. S. Levison, J. A. Buffa, E. Org, B. T. Sheehy, E. B. Britt, X. Fu, Y. Wu, L. Li, et al. 2013. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Medicine 19 (5):576–85. doi: 10.1038/nm.3145.
   PubMed Web of Science ®Google Scholar
• Kolodziejczyk, A. A., D. Zheng, O. Shibolet, and E. Elinav. 2019. The role of the microbiome in NAFLD and NASH. EMBO Molecular Medicine 11 (2):e9302. doi: 10.15252/emmm.201809302.
   PubMed Web of Science ®Google Scholar
• Krishnan, S., Y. Ding, N. Saedi, M. Choi, G. V. Sridharan, D. H. Sherr, M. L. Yarmush, R. C. Alaniz, A. Jayaraman, and K. Lee. 2018. Gut microbiota-derived tryptophan metabolites modulate inflammatory response in hepatocytes and macrophages. Cell Reports 23 (4):1099–111. doi: 10.1016/j.celrep.2018.03.109.
   PubMed Web of Science ®Google Scholar
• Kurdi, P., K. Kawanishi, K. Mizutani, and A. Yokota. 2006. Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria. Journal of Bacteriology 188 (5):1979–86. doi: 10.1128/jb.188.5.1979-1986.2006.
   PubMed Web of Science ®Google Scholar
• Lang, S., and B. Schnabl. 2020. Microbiota and fatty liver disease-the known, the unknown, and the future. Cell Host & Microbe 28 (2):233–44. doi: 10.1016/j.chom.2020.07.007.
   PubMed Web of Science ®Google Scholar
• Lau, J. K., X. Zhang, and J. Yu. 2017. Animal models of non-alcoholic fatty liver disease: Current perspectives and recent advances. The Journal of Pathology 241 (1):36–44. doi: 10.1002/path.4829.
   PubMed Web of Science ®Google Scholar
• Le Roy, T., M. Llopis, P. Lepage, A. Bruneau, S. Rabot, C. Bevilacqua, P. Martin, C. Philippe, F. Walker, A. Bado, et al. 2013. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62 (12):1787–94. doi: 10.1136/gutjnl-2012-303816.
   PubMed Web of Science ®Google Scholar
• Lee, G., H. J. You, J. S. Bajaj, S. K. Joo, J. Yu, S. Park, H. Kang, J. H. Park, J. H. Kim, D. H. Lee, et al. 2020a. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese nafld. Nature Communications 11 (1):4982. doi: 10.1038/s41467-020-18754-5.
   PubMed Web of Science ®Google Scholar
• Lee, N. Y., S. J. Yoon, D. H. Han, H. Gupta, G. S. Youn, M. J. Shin, Y. L. Ham, M. J. Kwak, B. Y. Kim, J. S. Yu, et al. 2020b. Lactobacillus and pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes 11 (4):882–99. doi: 10.1080/19490976.2020.1712984.
   PubMed Web of Science ®Google Scholar
• Lelouvier, B., F. Servant, S. Païssé, A. C. Brunet, S. Benyahya, M. Serino, C. Valle, M. R. Ortiz, J. Puig, M. Courtney, et al. 2016. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. Hepatology (Baltimore, Md.) 64 (6):2015–27. doi: 10.1002/hep.28829.
   PubMed Web of Science ®Google Scholar
• Lensu, S., R. Pariyani, E. Mäkinen, B. Yang, W. Saleem, E. Munukka, M. Lehti, A. Driuchina, J. Lindén, M. Tiirola, et al. 2020. Prebiotic xylo-oligosaccharides ameliorate high-fat-diet-induced hepatic steatosis in rats. Nutrients 12 (11):3225. doi: 10.3390/nu12113225.
   PubMed Web of Science ®Google Scholar
• Liang, W., K. Zhou, P. Jian, Z. Chang, Q. Zhang, Y. Liu, S. Xiao, and L. Zhang. 2021. Ginsenosides improve nonalcoholic fatty liver disease via integrated regulation of gut microbiota, inflammation and energy homeostasis. Frontiers in Pharmacology 12:622841. doi: 10.3389/fphar.2021.622841.
   PubMed Web of Science ®Google Scholar
• Li, F., C. Jiang, K. W. Krausz, Y. Li, I. Albert, H. Hao, K. M. Fabre, J. B. Mitchell, A. D. Patterson, and F. J. Gonzalez. 2013. Microbiome remodelling leads to inhibition of intestinal farnesoid x receptor signalling and decreased obesity. Nature Communications 4:2384. doi: 10.1038/ncomms3384.
   PubMed Web of Science ®Google Scholar
• Li, Y., J. Li, Q. Su, and Y. Liu. 2019. Sinapine reduces non-alcoholic fatty liver disease in mice by modulating the composition of the gut microbiota. Food & Function 10 (6):3637–49. doi: 10.1039/C9FO00195F.
   PubMed Web of Science ®Google Scholar
• Liu, H. Y., T. B. Walden, D. Cai, D. Ahl, S. Bertilsson, M. Phillipson, M. Nyman, and L. Holm. 2019. Dietary fiber in bilberry ameliorates pre-obesity events in rats by regulating lipid depot, cecal short-chain fatty acid formation and microbiota composition. Nutrients 11 (6):1350. doi: 10.3390/nu11061350.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Zúñiga, V., R. Bartolí, R. Planas, A. F. Hofmann, B. Viñado, L. R. Hagey, J. M. Hernández, J. Mañé, M. A. Alvarez, V. Ausina, et al. 2003. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 37 (3):551–7. doi: 10.1053/jhep.2003.50116.
   PubMed Web of Science ®Google Scholar
• Luther, J., J. J. Garber, H. Khalili, M. Dave, S. S. Bale, R. Jindal, D. L. Motola, S. Luther, S. Bohr, S. W. Jeoung, et al. 2015. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cellular and Molecular Gastroenterology and Hepatology 1 (2):222–32. doi: 10.1016/j.jcmgh.2015.01.001.
   PubMed Web of Science ®Google Scholar
• Ma, L., H. Li, J. Hu, J. Zheng, J. Zhou, R. Botchlett, D. Matthews, T. Zeng, L. Chen, X. Xiao, et al. 2020. Indole alleviates diet-induced hepatic steatosis and inflammation in a manner involving myeloid cell 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3. Hepatology (Baltimore, Md.) 72 (4):1191–203. doi: 10.1002/hep.31115.
   PubMed Web of Science ®Google Scholar
• Mantovani, A., G. Petracca, G. Beatrice, A. Csermely, H. Tilg, C. D. Byrne, and G. Targher. 2021. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: A meta-analysis of observational cohort studies. Gut. doi: 10.1136/gutjnl-2021-324191.
   Google Scholar
• Martens, E. C., M. Neumann, and M. S. Desai. 2018. Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier. Nature Reviews. Microbiology 16 (8):457–70. doi: 10.1038/s41579-018-0036-x.
   PubMed Web of Science ®Google Scholar
• Matsumoto, K., M. Ichimura, K. Tsuneyama, Y. Moritoki, H. Tsunashima, K. Omagari, M. Hara, I. Yasuda, H. Miyakawa, and K. Kikuchi. 2017. Fructo-oligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis. PloS One 12 (6):e0175406. doi: 10.1371/journal.pone.0175406.
   PubMed Web of Science ®Google Scholar
• Mcpherson, S., E. Henderson, A. D. Burt, C. P. Day, and Q. M. Anstee. 2014. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. Journal of Hepatology 60 (5):1055–62. doi: 10.1016/j.jhep.2014.01.010.
   PubMed Web of Science ®Google Scholar
• Michail, S., M. Lin, M. R. Frey, R. Fanter, O. Paliy, B. Hilbush, and N. V. Reo. 2015. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiology Ecology 91 (2):1–9. doi: 10.1093/femsec/fiu002.
   PubMed Web of Science ®Google Scholar
• Miura, K., Y. Kodama, S. Inokuchi, B. Schnabl, T. Aoyama, H. Ohnishi, J. M. Olefsky, D. A. Brenner, and E. Seki. 2010. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 139 (1):323–34.e7. doi: 10.1053/j.gastro.2010.03.052.
   PubMed Web of Science ®Google Scholar
• Miura, K., L. Yang, N. Van Rooijen, D. A. Brenner, H. Ohnishi, and E. Seki. 2013. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology (Baltimore, Md.) 57 (2):577–89. doi: 10.1002/hep.26081.
   PubMed Web of Science ®Google Scholar
• Monga Kravetz, A., T. Testerman, B. Galuppo, J. Graf, B. Pierpont, S. Siebel, R. Feinn, and N. Santoro. 2020. Effect of gut microbiota and pnpla3 rs738409 variant on nonalcoholic fatty liver disease (nafld) in obese youth. Journal of Clinical Endocrinology and Metabolism 105 (10):dgaa382. doi: 10.1210/clinem/dgaa382.
   PubMed Web of Science ®Google Scholar
• Moro-Sibilot, L., P. Blanc, M. Taillardet, E. Bardel, C. Couillault, G. Boschetti, A. Traverse-Glehen, T. Defrance, D. Kaiserlian, and B. Dubois. 2016. Mouse and human liver contain immunoglobulin a-secreting cells originating from peyer’s patches and directed against intestinal antigens. Gastroenterology 151 (2):311–23. doi: 10.1053/j.gastro.2016.04.014.
   PubMed Web of Science ®Google Scholar
• Morze, J., M. Koch, S. A. Aroner, M. Budoff, R. L. Mcclelland, K. J. Mukamal, and M. K. Jensen. 2020. Associations of hdl subspecies defined by apoc3 with non-alcoholic fatty liver disease: The multi-ethnic study of atherosclerosis. Journal of Clinical Medicine 9 (11):3522. doi: 10.3390/jcm9113522.
   PubMed Web of Science ®Google Scholar
• Mouries, J., P. Brescia, A. Silvestri, I. Spadoni, M. Sorribas, R. Wiest, E. Mileti, M. Galbiati, P. Invernizzi, L. Adorini, et al. 2019. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. Journal of Hepatology 71 (6):1216–28. doi: 10.1016/j.jhep.2019.08.005.
   PubMed Web of Science ®Google Scholar
• Mu, J., F. Tan, X. Zhou, and X. Zhao. 2020. Lactobacillus fermentum cqpc06 in naturally fermented pickles prevents non-alcoholic fatty liver disease by stabilizing the gut-liver axis in mice. Food & Function 11 (10):8707–23. doi: 10.1039/d0fo01823f.
   PubMed Web of Science ®Google Scholar
• Mu, H. N., Q. Zhou, R. Y. Yang, W. Q. Tang, H. X. Li, S. M. Wang, J. Li, W. X. Chen, and J. Dong. 2021. Caffeic acid prevents non-alcoholic fatty liver disease induced by a high-fat diet through gut microbiota modulation in mice. Food Research International (Ottawa, Ont.) 143:110240. doi: 10.1016/j.foodres.2021.110240.
   PubMed Web of Science ®Google Scholar
• Newsome, P. N., K. Buchholtz, K. Cusi, M. Linder, T. Okanoue, V. Ratziu, A. J. Sanyal, A. S. Sejling, and S. A. Harrison. 2021. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. New England Journal of Medicine 384 (12):1113–24. doi: 10.1056/NEJMoa2028395.
   PubMed Web of Science ®Google Scholar
• Noval Rivas, M., D. Wakita, M. K. Franklin, T. T. Carvalho, A. Abolhesn, A. C. Gomez, M. C. Fishbein, S. Chen, T. J. Lehman, K. Sato, et al. 2019. Intestinal permeability and iga provoke immune vasculitis linked to cardiovascular inflammation. Immunity 51 (3):508–21.e6. doi: 10.1016/j.immuni.2019.05.021.
   PubMed Web of Science ®Google Scholar
• Okai, S., F. Usui, M. Ohta, H. Mori, K. Kurokawa, S. Matsumoto, T. Kato, E. Miyauchi, H. Ohno, and R. Shinkura. 2017. Intestinal iga as a modulator of the gut microbiota. Gut Microbes 8 (5):486–92. doi: 10.1080/19490976.2017.1310357.
   PubMed Web of Science ®Google Scholar
• Ottosson, F., L. Brunkwall, U. Ericson, P. M. Nilsson, P. Almgren, C. Fernandez, O. Melander, and M. Orho-Melander. 2018. Connection between bmi-related plasma metabolite profile and gut microbiota. The Journal of Clinical Endocrinology & Metabolism 103 (4):1491–501. doi: 10.1210/jc.2017-02114.
   PubMed Web of Science ®Google Scholar
• Pabst, O., and E. Slack. 2020. Iga and the intestinal microbiota: The importance of being specific. Mucosal Immunology 13 (1):12–21. doi: 10.1038/s41385-019-0227-4.
   PubMed Web of Science ®Google Scholar
• Pachikian, B. D., A. Essaghir, J. B. Demoulin, E. Catry, A. M. Neyrinck, E. M. Dewulf, F. M. Sohet, L. Portois, L. A. Clerbaux, Y. A. Carpentier, et al. 2013. Prebiotic approach alleviates hepatic steatosis: Implication of fatty acid oxidative and cholesterol synthesis pathways. Molecular Nutrition & Food Research 57 (2):347–59. doi: 10.1002/mnfr.201200364.
   PubMed Web of Science ®Google Scholar
• Pan, Q., S. Lin, Y. Li, L. Liu, X. Li, X. Gao, J. Yan, B. Gu, X. Chen, W. Li, et al. 2021. A novel glp-1 and fgf21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. EBioMedicine 63:103202. doi: 10.1016/j.ebiom.2020.103202.
   PubMed Web of Science ®Google Scholar
• Park, E. J., Y. S. Lee, S. M. Kim, G. S. Park, Y. H. Lee, D. Y. Jeong, J. Kang, and H. J. Lee. 2020. Beneficial effects of lactobacillus plantarum strains on non-alcoholic fatty liver disease in high fat/high fructose diet-fed rats. Nutrients 12 (2):542. doi: 10.3390/nu12020542.
   PubMed Web of Science ®Google Scholar
• Parséus, A., N. Sommer, F. Sommer, R. Caesar, A. Molinaro, M. Ståhlman, T. U. Greiner, R. Perkins, and F. Bäckhed. 2017. Microbiota-induced obesity requires farnesoid x receptor. Gut 66 (3):429–37. doi: 10.1136/gutjnl-2015-310283.
   PubMed Web of Science ®Google Scholar
• Pedersen, H. K., V. Gudmundsdottir, H. B. Nielsen, T. Hyotylainen, T. Nielsen, B. A. Jensen, K. Forslund, F. Hildebrand, E. Prifti, G. Falony, et al. 2016. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535 (7612):376–81. doi: 10.1038/nature18646.
   PubMed Web of Science ®Google Scholar
• Ponziani, F. R., S. Bhoori, C. Castelli, L. Putignani, L. Rivoltini, F. Del Chierico, M. Sanguinetti, D. Morelli, F. Paroni Sterbini, V. Petito, et al. 2019. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.) 69 (1):107–20. doi: 10.1002/hep.30036.
   PubMed Web of Science ®Google Scholar
• Porras, D., E. Nistal, S. Martínez-Flórez, J. L. Olcoz, R. Jover, F. Jorquera, J. González-Gallego, M. V. García-Mediavilla, and S. Sánchez-Campos. 2019. Functional interactions between gut microbiota transplantation, quercetin, and high-fat diet determine non-alcoholic fatty liver disease development in germ-free mice. Molecular Nutrition & Food Research 63 (8):e1800930 doi: 10.1002/mnfr.201800930.
   PubMed Web of Science ®Google Scholar
• Porras, D., E. Nistal, S. Martínez-Flórez, S. Pisonero-Vaquero, J. L. Olcoz, R. Jover, J. González-Gallego, M. V. García-Mediavilla, and S. Sánchez-Campos. 2017. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Free Radical Biology and Medicine 102:188–202. doi: 10.1016/j.freeradbiomed.2016.11.037.
   PubMed Web of Science ®Google Scholar
• Puri, P., K. Daita, A. Joyce, F. Mirshahi, P. K. Santhekadur, S. Cazanave, V. A. Luketic, M. S. Siddiqui, S. Boyett, H. K. Min, et al. 2018. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology (Baltimore, Md.) 67 (2):534–48. doi: 10.1002/hep.29359.
   PubMed Web of Science ®Google Scholar
• Reigstad, C. S., C. E. Salmonson, J. F. Rainey, 3rd, J. H. Szurszewski, D. R. Linden, J. L. Sonnenburg, G. Farrugia, and P. C. Kashyap. 2015. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. The FASEB Journal 29 (4):1395–403. doi: 10.1096/fj.14-259598.
   PubMed Web of Science ®Google Scholar
• Ridlon, J. M., D. J. Kang, P. B. Hylemon, and J. S. Bajaj. 2014. Bile acids and the gut microbiome. Current Opinion in Gastroenterology 30 (3):332–8. doi: 10.1097/mog.0000000000000057.
   PubMed Web of Science ®Google Scholar
• Rivera, C. A., L. Gaskin, M. Allman, J. Pang, K. Brady, P. Adegboyega, and K. Pruitt. 2010. Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis. BMC Gastroenterology 10:52. doi: 10.1186/1471-230x-10-52.
   PubMed Web of Science ®Google Scholar
• Robinson, M. W., C. Harmon, and C. O’farrelly. 2016. Liver immunology and its role in inflammation and homeostasis. Cellular & Molecular Immunology 13 (3):267–76. doi: 10.1038/cmi.2016.3.
   PubMed Web of Science ®Google Scholar
• Rodrigues, R. R., M. Gurung, Z. Li, M. García-Jaramillo, R. Greer, C. Gaulke, F. Bauchinger, H. You, J. W. Pederson, S. Vasquez-Perez, et al. 2021. Transkingdom interactions between lactobacilli and hepatic mitochondria attenuate western diet-induced diabetes. Nature Communications 12 (1):101. doi: 10.1038/s41467-020-20313-x.
   PubMed Web of Science ®Google Scholar
• Rustgi, V. K., Y. Li, K. Gupta, C. D. Minacapelli, A. Bhurwal, C. Catalano, and M. I. Elsaid. 2021. Bariatric surgery reduces cancer risk in adults with nonalcoholic fatty liver disease and severe obesity. Gastroenterology 161 (1):171–84.e10. doi: 10.1053/j.gastro.2021.03.021.
   PubMed Web of Science ®Google Scholar
• Salunkhe, S. A., D. Chitkara, R. I. Mahato, and A. Mittal. 2021. Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis. Advanced Drug Delivery Reviews 173:394–415. doi: 10.1016/j.addr.2021.04.003.
   PubMed Web of Science ®Google Scholar
• Sanna, S., N. R. Van Zuydam, A. Mahajan, A. Kurilshikov, A. Vich Vila, U. Võsa, Z. Mujagic, A. a M. Masclee, D. Jonkers, M. Oosting, et al. 2019. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nature Genetics 51 (4):600–5. doi: 10.1038/s41588-019-0350-x.
   PubMed Web of Science ®Google Scholar
• Sayin, S. I., A. Wahlstrom, J. Felin, S. Jantti, H. U. Marschall, K. Bamberg, B. Angelin, T. Hyotylainen, M. Oresic, and F. Backhed. 2013. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring fxr antagonist. Cell Metabolism 17 (2):225–35. doi: 10.1016/j.cmet.2013.01.003.
   PubMed Web of Science ®Google Scholar
• Schierwagen, R., C. Alvarez-Silva, M. S. A. Madsen, C. C. Kolbe, C. Meyer, D. Thomas, F. E. Uschner, F. Magdaleno, C. Jansen, A. Pohlmann, et al. 2019. Circulating microbiome in blood of different circulatory compartments. Gut 68 (3):578–80. doi: 10.1136/gutjnl-2018-316227.
   PubMed Web of Science ®Google Scholar
• Schwabe, R. F., and T. F. Greten. 2020. Gut microbiome in hcc - mechanisms, diagnosis and therapy. Journal of Hepatology 72 (2):230–8. doi: 10.1016/j.jhep.2019.08.016.
   PubMed Web of Science ®Google Scholar
• Scorletti, E., P. R. Afolabi, E. A. Miles, D. E. Smith, A. Almehmadi, A. Alshathry, C. E. Childs, S. Del Fabbro, J. Bilson, H. E. Moyses, et al. 2020. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology 158 (6):1597–610.e7. doi: 10.1053/j.gastro.2020.01.031.
   PubMed Web of Science ®Google Scholar
• Scott, S. A., J. Fu, and P. V. Chang. 2020. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences of the United States of America 117 (32):19376–87. doi: 10.1073/pnas.2000047117.
   PubMed Web of Science ®Google Scholar
• Seki, E., S. De Minicis, C. H. Osterreicher, J. Kluwe, Y. Osawa, D. A. Brenner, and R. F. Schwabe. 2007. Tlr4 enhances tgf-beta signaling and hepatic fibrosis. Nature Medicine 13 (11):1324–32. doi: 10.1038/nm1663.
   PubMed Web of Science ®Google Scholar
• Sharpton, S. R., V. Ajmera, and R. Loomba. 2019. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: From composition to function. Clinical Gastroenterology and Hepatology 17 (2):296–306. doi: 10.1016/j.cgh.2018.08.065.
   PubMed Web of Science ®Google Scholar
• Sharpton, S. R., B. Schnabl, R. Knight, and R. Loomba. 2021. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease. Cell Metabolism 33 (1):21–32. doi: 10.1016/j.cmet.2020.11.010.
   PubMed Web of Science ®Google Scholar
• Shen, F., R. D. Zheng, X. Q. Sun, W. J. Ding, X. Y. Wang, and J. G. Fan. 2017. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary & Pancreatic Diseases International 16 (4):375–81. doi: 10.1016/S1499-3872(17)60019-5.
   PubMed Web of Science ®Google Scholar
• Shi, Z., G. Chen, Z. Cao, F. Wu, H. Lei, C. Chen, Y. Song, C. Liu, J. Li, J. Zhou, et al. 2021. Gut microbiota and its metabolite deoxycholic acid contribute to sucralose consumption-induced nonalcoholic fatty liver disease. Journal of Agricultural and Food Chemistry 69 (13):3982–91. doi: 10.1021/acs.jafc.0c07467.
   PubMed Web of Science ®Google Scholar
• Soderborg, T. K., S. E. Clark, C. E. Mulligan, R. C. Janssen, L. Babcock, D. Ir, B. Young, N. Krebs, D. J. Lemas, L. K. Johnson, et al. 2018. The gut microbiota in infants of obese mothers increases inflammation and susceptibility to nafld. Nature Communications 9 (1):4462. doi: 10.1038/s41467-018-06929-0.
   PubMedGoogle Scholar
• Sokol, H., P. Seksik, J. P. Furet, O. Firmesse, I. Nion-Larmurier, L. Beaugerie, J. Cosnes, G. Corthier, P. Marteau, and J. Doré. 2009. Low counts of faecalibacterium prausnitzii in colitis microbiota. Inflammatory Bowel Disease 15 (8):1183–9. doi: 10.1002/ibd.20903.
   PubMed Web of Science ®Google Scholar
• Spencer, M. D., T. J. Hamp, R. W. Reid, L. M. Fischer, S. H. Zeisel, and A. A. Fodor. 2011. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 140 (3):976–86. doi: 10.1053/j.gastro.2010.11.049.
   PubMed Web of Science ®Google Scholar
• Stachowska, E., P. Portincasa, D. Jamioł-Milc, D. Maciejewska-Markiewicz, and K. Skonieczna-Żydecka. 2020. The relationship between prebiotic supplementation and anthropometric and biochemical parameters in patients with nafld-a systematic review and meta-analysis of randomized controlled trials. Nutrients 12 (11):3460. doi: 10.3390/nu12113460.
   PubMed Web of Science ®Google Scholar
• Szabo, G., A. Velayudham, L. Romics, Jr., and P. Mandrekar. 2005. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: The role of toll-like receptors 2 and 4. Alcoholism, Clinical and Experimental Research 29 (11 Suppl):140S–5S. doi: 10.1097/01.alc.0000189287.83544.33.
   PubMed Web of Science ®Google Scholar
• Takayama, S., K. Katada, T. Takagi, T. Iida, T. Ueda, K. Mizushima, Y. Higashimura, M. Morita, T. Okayama, K. Kamada, et al. 2021. Partially hydrolyzed guar gum attenuates non-alcoholic fatty liver disease in mice through the gut-liver axis. World Journal of Gastroenterology 27 (18):2160–76. doi: 10.3748/wjg.v27.i18.2160.
   PubMed Web of Science ®Google Scholar
• Tan, X., Y. Liu, J. Long, S. Chen, G. Liao, S. Wu, C. Li, L. Wang, W. Ling, and H. Zhu. 2019. Trimethylamine n-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid x receptor signaling in nonalcoholic fatty liver disease. Molecular Nutrition & Food Research 63 (17):e1900257. doi: 10.1002/mnfr.201900257.
   PubMed Web of Science ®Google Scholar
• Ullmer, C., R. Alvarez Sanchez, U. Sprecher, S. Raab, P. Mattei, H. Dehmlow, S. Sewing, A. Iglesias, J. Beauchamp, and K. Conde-Knape. 2013. Systemic bile acid sensing by g protein-coupled bile acid receptor 1 (gpbar1) promotes pyy and glp-1 release. British Journal of Pharmacology 169 (3):671–84. doi: 10.1111/bph.12158.
   PubMed Web of Science ®Google Scholar
• Venkatesh, M., S. Mukherjee, H. Wang, H. Li, K. Sun, A. P. Benechet, Z. Qiu, L. Maher, M. R. Redinbo, R. S. Phillips, et al. 2014. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor pxr and toll-like receptor 4. Immunity 41 (2):296–310. doi: 10.1016/j.immuni.2014.06.014.
   PubMed Web of Science ®Google Scholar
• Volynets, V., J. Machann, M. A. Küper, I. B. Maier, A. Spruss, A. Königsrainer, S. C. Bischoff, and I. Bergheim. 2013. A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (nafld): A pilot study. European Journal of Nutrition 52 (2):527–35. doi: 10.1007/s00394-012-0355-z.
   PubMed Web of Science ®Google Scholar
• Wahlström, A., S. I. Sayin, H. U. Marschall, and F. Bäckhed. 2016. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metabolism 24 (1):41–50. doi: 10.1016/j.cmet.2016.05.005.
   PubMed Web of Science ®Google Scholar
• Wang, B., X. Jiang, M. Cao, J. Ge, Q. Bao, L. Tang, Y. Chen, and L. Li. 2016. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Scientific Reports 6:32002. doi: 10.1038/srep32002.
   PubMed Web of Science ®Google Scholar
• Wang, G., T. Jiao, Y. Xu, D. Li, Q. Si, J. Hao, J. Zhao, H. Zhang, and W. Chen. 2020a. Bifidobacterium adolescentis and lactobacillus rhamnosus alleviate non-alcoholic fatty liver disease induced by a high-fat, high-cholesterol diet through modulation of different gut microbiota-dependent pathways. Food & Function 11 (7):6115–27. doi: 10.1039/c9fo02905b.
   PubMedGoogle Scholar
• Wang, R., R. Tang, B. Li, X. Ma, B. Schnabl, and H. Tilg. 2021. Gut microbiome, liver immunology, and liver diseases. Cellular & Molecular Immunology 18 (1):4–17. doi: 10.1038/s41423-020-00592-6.
   PubMed Web of Science ®Google Scholar
• Wang, W., A. L. Xu, Z. C. Li, Y. Li, S. F. Xu, H. C. Sang, and F. Zhi. 2020b. Combination of probiotics and salvia miltiorrhiza polysaccharide alleviates hepatic steatosis via gut microbiota modulation and insulin resistance improvement in high fat-induced nafld mice. Diabetes & Metabolism Journal 44 (2):336–48. doi: 10.4093/dmj.2019.0042.
   PubMed Web of Science ®Google Scholar
• Watanabe, M., S. M. Houten, L. Wang, A. Moschetta, D. J. Mangelsdorf, R. A. Heyman, D. D. Moore, and J. Auwerx. 2004. Bile acids lower triglyceride levels via a pathway involving fxr, shp, and srebp-1c. The Journal of Clinical Investigation 113 (10):1408–18. doi: 10.1172/jci21025.
   PubMed Web of Science ®Google Scholar
• Weber, D., P. J. Oefner, A. Hiergeist, J. Koestler, A. Gessner, M. Weber, J. Hahn, D. Wolff, F. Stämmler, R. Spang, et al. 2015. Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome. Blood 126 (14):1723–8. doi: 10.1182/blood-2015-04-638858.
   PubMed Web of Science ®Google Scholar
• Willemsen, L. E., M. A. Koetsier, S. J. Van Deventer, and E. A. Van Tol. 2003. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin e(1) and e(2) production by intestinal myofibroblasts. Gut 52 (10):1442–7. doi: 10.1136/gut.52.10.1442.
   PubMed Web of Science ®Google Scholar
• Wu, W., M. Sun, F. Chen, A. T. Cao, H. Liu, Y. Zhao, X. Huang, Y. Xiao, S. Yao, Q. Zhao, et al. 2017. Microbiota metabolite short-chain fatty acid acetate promotes intestinal iga response to microbiota which is mediated by gpr43. Mucosal Immunology 10 (4):946–56. doi: 10.1038/mi.2016.114.
   PubMed Web of Science ®Google Scholar
• Xia, W., I. Khan, X. A. Li, G. Huang, Z. Yu, W. K. Leong, R. Han, L. T. Ho, and W. L. Wendy Hsiao. 2020. Adaptogenic flower buds exert cancer preventive effects by enhancing the scfa-producers, strengthening the epithelial tight junction complex and immune responses. Pharmacological Research 159:104809. doi: 10.1016/j.phrs.2020.104809.
   PubMed Web of Science ®Google Scholar
• Xue, C., Y. Li, H. Lv, L. Zhang, C. Bi, N. Dong, A. Shan, and J. Wang. 2021. Oleanolic acid targets the gut-liver axis to alleviate metabolic disorders and hepatic steatosis. Journal of Agricultural and Food Chemistry 69 (28):7884–97. doi: 10.1021/acs.jafc.1c02257.
   PubMed Web of Science ®Google Scholar
• Yang, Y., Y. Chang, Y. Wu, H. Liu, Q. Liu, Z. Kang, M. Wu, H. Yin, and J. Duan. 2021. A homogeneous polysaccharide from lycium barbarum: Structural characterizations, anti-obesity effects and impacts on gut microbiota. International Journal of Biological Macromolecules 183:2074–87. doi: 10.1016/j.ijbiomac.2021.05.209.
   PubMed Web of Science ®Google Scholar
• Yang, J. M., Y. Sun, M. Wang, X. L. Zhang, S. J. Zhang, Y. S. Gao, L. Chen, M. Y. Wu, L. Zhou, Y. M. Zhou, et al. 2019. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World Journal of Gastroenterology 25 (34):5105–19. doi: 10.3748/wjg.v25.i34.5105.
   PubMed Web of Science ®Google Scholar
• Yano, J. M., K. Yu, G. P. Donaldson, G. G. Shastri, P. Ann, L. Ma, C. R. Nagler, R. F. Ismagilov, S. K. Mazmanian, and E. Y. Hsiao. 2015. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161 (2):264–76. doi: 10.1016/j.cell.2015.02.047.
   PubMed Web of Science ®Google Scholar
• Ye, H., Q. Li, Z. Zhang, M. Sun, C. Zhao, and T. Zhang. 2017. Effect of a novel potential probiotic lactobacillus paracasei jlus66 isolated from fermented milk on nonalcoholic fatty liver in rats. Food & Function 8 (12):4539–46. doi: 10.1039/c7fo01108c.
   PubMed Web of Science ®Google Scholar
• Ye, J., L. Lv, W. Wu, Y. Li, D. Shi, D. Fang, F. Guo, H. Jiang, R. Yan, W. Ye, et al. 2018a. Butyrate protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis by improving gut barrier function, attenuating inflammation and reducing endotoxin levels. Frontiers in Microbiology 9:1967. doi: 10.3389/fmicb.2018.01967.
   PubMed Web of Science ®Google Scholar
• Ye, J. Z., Y. T. Li, W. R. Wu, D. Shi, D. Q. Fang, L. Y. Yang, X. Y. Bian, J. J. Wu, Q. Wang, X. W. Jiang, et al. 2018b. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis. World Journal of Gastroenterology 24 (23):2468–81. doi: 10.3748/wjg.v24.i23.2468.
   PubMed Web of Science ®Google Scholar
• Yiu, J. H. C., K. S. Chan, J. Cheung, J. Li, Y. Liu, Y. Wang, W. W. L. Fung, J. Cai, S. W. M. Cheung, B. Dorweiler, et al. 2020. Gut microbiota-associated activation of tlr5 induces apolipoprotein a1 production in the liver. Circulation Research 127 (10):1236–52. doi: 10.1161/circresaha.120.317362.
   PubMed Web of Science ®Google Scholar
• Yuan, J., C. Chen, J. Cui, J. Lu, C. Yan, X. Wei, X. Zhao, N. Li, S. Li, G. Xue, et al. 2019. Fatty liver disease caused by high-alcohol-producing klebsiella pneumoniae. Cell Metabolism 30 (4):675–88.e7. doi: 10.1016/j.cmet.2019.08.018.
   PubMed Web of Science ®Google Scholar
• Zarate, M. A., L. M. Nguyen, R. K. De Dios, L. Zheng, and C. J. Wright. 2020. Maturation of the acute hepatic tlr4/nf-κb mediated innate immune response is p65 dependent in mice. Frontiers in Immunology 11:1892. doi: 10.3389/fimmu.2020.01892.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., X. Chen, and B. Cui. 2021. Modulation of the fecal microbiome and metabolome by resistant dextrin ameliorates hepatic steatosis and mitochondrial abnormalities in mice. Food & Function 12 (10):4504–18. doi: 10.1039/d1fo00249j.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., C. Ran, Q. W. Ding, H. L. Liu, M. X. Xie, Y. L. Yang, Y. D. Xie, C. C. Gao, H. L. Zhang, and Z. G. Zhou. 2019. Ability of prebiotic polysaccharides to activate a hif1α-antimicrobial peptide axis determines liver injury risk in zebrafish. Communications Biology 2:274. doi: 10.1038/s42003-019-0526-z.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., X. Xu, W. Tian, R. Jiang, Y. Lu, Q. Sun, R. Fu, Q. He, J. Wang, Y. Liu, et al. 2020. Arrb1 inhibits non-alcoholic steatohepatitis progression by promoting gdf15 maturation. Journal of Hepatology 72 (5):976–89. doi: 10.1016/j.jhep.2019.12.004.
   PubMed Web of Science ®Google Scholar
• Zhang, F., S. Zhao, W. Yan, Y. Xia, X. Chen, W. Wang, J. Zhang, C. Gao, C. Peng, F. Yan, et al. 2016. Branched chain amino acids cause liver injury in obese/diabetic mice by promoting adipocyte lipolysis and inhibiting hepatic autophagy. EBioMedicine 13:157–67. doi: 10.1016/j.ebiom.2016.10.013.
   PubMed Web of Science ®Google Scholar
• Zhao, S., C. Jang, J. Liu, K. Uehara, M. Gilbert, L. Izzo, X. Zeng, S. Trefely, S. Fernandez, A. Carrer, et al. 2020a. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature 579 (7800):586–91. doi: 10.1038/s41586-020-2101-7.
   PubMed Web of Science ®Google Scholar
• Zhao, Z., L. Chen, Y. Zhao, C. Wang, C. Duan, G. Yang, C. Niu, and S. Li. 2020b. Lactobacillus plantarum na136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation. Applied Microbiology and Biotechnology 104 (12):5273–82. doi: 10.1007/s00253-020-10633-9.
   PubMed Web of Science ®Google Scholar
• Zhao, C., L. Liu, Q. Liu, F. Li, L. Zhang, F. Zhu, T. Shao, S. Barve, Y. Chen, X. Li, et al. 2019a. Fibroblast growth factor 21 is required for the therapeutic effects of lactobacillus rhamnosus gg against fructose-induced fatty liver in mice. Molecular Metabolism 29:145–57. doi: 10.1016/j.molmet.2019.08.020.
   PubMed Web of Science ®Google Scholar
• Zhao, Z. H., F. Z. Xin, Y. Xue, Z. Hu, Y. Han, F. Ma, D. Zhou, X. L. Liu, A. Cui, Z. Liu, et al. 2019b. Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. Experimental & Molecular Medicine 51 (9):1–14. doi: 10.1038/s12276-019-0304-5.
   Google Scholar
• Zhao, Z. H., F. Z. Xin, D. Zhou, Y. Q. Xue, X. L. Liu, R. X. Yang, Q. Pan, and J. G. Fan. 2019c. Trimethylamine n-oxide attenuates high-fat high-cholesterol diet-induced steatohepatitis by reducing hepatic cholesterol overload in rats. World Journal of Gastroenterology 25 (20):2450–62. doi: 10.3748/wjg.v25.i20.2450.
   PubMed Web of Science ®Google Scholar
• Zhong, F., X. Zhou, J. Xu, and L. Gao. 2020. Rodent models of nonalcoholic fatty liver disease. Digestion 101 (5):522–35. doi: 10.1159/000501851.
   PubMed Web of Science ®Google Scholar
• Zhou, X., D. Han, R. Xu, S. Li, H. Wu, C. Qu, F. Wang, X. Wang, and Y. Zhao. 2014. A model of metabolic syndrome and related diseases with intestinal endotoxemia in rats fed a high fat and high sucrose diet. PloS One 9 (12):e115148. doi: 10.1371/journal.pone.0115148.
   PubMed Web of Science ®Google Scholar
• Zhou, D., Q. Pan, F. Shen, H. X. Cao, W. J. Ding, Y. W. Chen, and J. G. Fan. 2017a. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Scientific Reports 7 (1):1529. doi: 10.1038/s41598-017-01751-y.
   PubMedGoogle Scholar
• Zhou, D., Q. Pan, F. Z. Xin, R. N. Zhang, C. X. He, G. Y. Chen, C. Liu, Y. W. Chen, and J. G. Fan. 2017b. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. World Journal of Gastroenterology 23 (1):60–75. doi: 10.3748/wjg.v23.i1.60.
   PubMed Web of Science ®Google Scholar
• Zhu, L., S. S. Baker, C. Gill, W. Liu, R. Alkhouri, R. D. Baker, and S. R. Gill. 2013. Characterization of gut microbiomes in nonalcoholic steatohepatitis (nash) patients: A connection between endogenous alcohol and nash. Hepatology (Baltimore, Md.) 57 (2):601–9. doi: 10.1002/hep.29.3.
   PubMed Web of Science ®Google Scholar